Merck Serono

Results: 49



#Item
41SSPA[removed]Advanced Analytical Methodologies in Chemical Drug Manufacturing Tuesday, September 23, [removed]Registration

SSPA[removed]Advanced Analytical Methodologies in Chemical Drug Manufacturing Tuesday, September 23, [removed]Registration

Add to Reading List

Source URL: users2.unimi.it

Language: English - Date: 2014-07-01 00:43:36
421  Author Conflict of Interest Statements Author Name  Topics Authored

1 Author Conflict of Interest Statements Author Name Topics Authored

Add to Reading List

Source URL: www.essentialevidenceplus.com

Language: English - Date: 2010-02-11 14:23:12
43Your Contact  Gangolf Schrimpf +[removed]Investor Relations +[removed]News Release

Your Contact Gangolf Schrimpf +[removed]Investor Relations +[removed]News Release

Add to Reading List

Source URL: static.tue.nl

Language: English - Date: 2014-06-30 06:42:22
44Paper SP06  On the use of spreadsheets in statistical analysis Martin Gregory, Merck Serono, Darmstadt, Germany  1

Paper SP06 On the use of spreadsheets in statistical analysis Martin Gregory, Merck Serono, Darmstadt, Germany 1

Add to Reading List

Source URL: www.phusewiki.org

Language: English - Date: 2012-11-30 11:14:21
45NEWS  in brief The European Union granted €9 ($12.1) million to WatBio, a 5-year project aimed at producing drought-resistant plants for

NEWS in brief The European Union granted €9 ($12.1) million to WatBio, a 5-year project aimed at producing drought-resistant plants for

Add to Reading List

Source URL: www.europabio.org

Language: English - Date: 2013-03-19 07:30:36
46Merck KGaA  JSJ INCHEON : D2006[removed].

Merck KGaA JSJ INCHEON : D2006[removed].

Add to Reading List

Source URL: www.wipo.int

Language: English - Date: 2007-04-10 05:02:52
47Merck KGaA  JSJ Incheon : D2006-1541

Merck KGaA JSJ Incheon : D2006-1541

Add to Reading List

Source URL: www.wipo.int

Language: English - Date: 2007-04-10 05:02:42
48ABLYNX ANNOUNCES WORLDWIDE CANCER IMMUNOTHERAPY DISCOVERY COLLABORATION AND LICENSING AGREEMENT WITH MERCK Utilising the Nanobody® technology to generate multi-specific drugs GHENT, Belgium, February 3, 2014 –Ablynx [

ABLYNX ANNOUNCES WORLDWIDE CANCER IMMUNOTHERAPY DISCOVERY COLLABORATION AND LICENSING AGREEMENT WITH MERCK Utilising the Nanobody® technology to generate multi-specific drugs GHENT, Belgium, February 3, 2014 –Ablynx [

Add to Reading List

Source URL: hugin.info

Language: English - Date: 2014-02-02 12:55:18
49June[removed]in association with

June[removed]in association with

Add to Reading List

Source URL: www.spinoutsuk.co.uk

Language: English - Date: 2013-09-03 09:25:59